Wednesday, September 16, 2026Latest filing Sep 14, 2026

ORMP Congressional Stock Trades

Oramed Pharmaceuticals Inc. - Common Stock (ORMP)

Last disclosed trade Jan 10

Every disclosed trade in ORMP by members of Congress under the STOCK Act, parsed by Coldpine. Informational only, sourced from public filings. Not investment advice.

Sample · the intelligence layer

Coldpine signal scoreA 0-1 composite from four weighted factors: disclosure speed, trade size, cluster activity (multiple members buying the same name), and the member’s track record. ≥ 0.65 is the high-conviction tier; ≥ 0.50 is moderate. Trades from trust-managed members are penalized (× 0.2 multiplier). It’s research, not a recommendation.

Brad Knott · Sold $ORMP · Jan 10 · $15K–$50K

0.28LOW
Disclosure speedx 0.250.10
Trade sizex 0.250.50
Cluster activityx 0.150.00
Track recordx 0.350.38

Every disclosed trade in the database gets this treatment: a four-factor score and a written read from Coldpine’s AI-based analysis. Informational only, not investment advice. Create a free account for every scored trade →

Follow $ORMP

Get notified when any member of Congress trades $ORMP. Free, no card, no spam.

Follow free →
1
Disclosed trades
0
Buys
1
Sells
1
Members trading

The record on $ORMP

Coldpine has parsed 1 disclosed trade in $ORMP by 1 member of Congress, drawn from 1 periodic transaction report dated Jan 10, 2025. It came from the House, filed by a Republican.

The one trade with a known filing lag was reported 46 days after the trade date, outside the 45-day window the STOCK Act sets: a $ORMP sale by Brad Knott dated Jan 10, 2025, disclosed Feb 25, 2025. How late filing is measured across all of Congress is in the late-filers study.

The one trade that lists an account holder was reported under the member directly, not a spouse, dependent child, or joint account.

Members who trade ORMP

Recent disclosed trades in ORMP

DateMemberTypeAmount
Jan 10Brad Knott(NC)sell$15K–$50K

Data sourced from public STOCK Act disclosures. Coldpine is a publisher of intelligence on congressional disclosures, not an investment adviser. See full history and scores, free with an account →